Navigation Links
Thermage, Inc. to Present at the 2008 Thomas Weisel Partners Healthcare Conference
Date:8/27/2008

HAYWARD, Calif., Aug. 27 /PRNewswire-FirstCall/ -- Thermage, Inc. (Nasdaq: THRM), a leader in non-invasive tissue tightening in the aesthetic industry, announced today that it will present at the 2008 Thomas Weisel Partners Healthcare Conference at the Four Seasons Hotel in Boston. The Company's presentation is scheduled for Wednesday, September 3, 2008 at 4:25 p.m. Eastern Time. Stephen Fanning, Chairman, President and Chief Executive Officer of Thermage, will review the company's business strategy and historical financial results.

Attendance at the conference is by invitation only. Thermage will offer a live audio webcast of its presentation, which may be accessed at the Company's website at http://www.thermage.com. An archived replay of the presentation will be available following the live presentation for 30 days and will also be available at http://www.thermage.com.

About Thermage

Thermage's innovative technology provides a unique non-invasive procedure designed to tighten and contour skin, significantly expanding the non-invasive aesthetic applications physicians can offer to the rapidly growing "anti-aging" market. For more information about Thermage, call 1-510-259-7117 or log on to http://www.thermage.com.


'/>"/>
SOURCE Thermage, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Thermage, Inc. to Present at the 10th Annual Needham & Company Growth Conference
2. Thermage, Inc. Announces Second Quarter 2008 Results Release Date and Conference Call
3. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
4. Avicena Group to Present at Noble Financial Conference
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CEL-SCI to Present at the Noble Financial Conference
9. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
10. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
11. Strategic Diagnostics Updates Roth Conference Presentation Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014  Xencor, Inc. (NASDAQ: ... monoclonal antibodies for the treatment of autoimmune diseases, ... the appointment of Debra Zack , M.D., ... of Lloyd Rowland , senior vice president, ... "Debra,s expertise in biologics clinical development and ...
(Date:9/2/2014)... 2014  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... candidates targeting specific pathogens that cause serious infections ... final preclinical toxicology study of SYN-004. Per U.S. ... study was required to move the Company,s lead ... devastating effects of Clostridium difficile (C. difficile), ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 PMG ... its 11th clinical research site: PMG Research of Rocky ... and operation of the clinical research department at ... PMG’s presence in eastern North Carolina. This new site ... the patients in Rocky Mount and the surrounding communities, ...
(Date:9/2/2014)... , September 2, 2014 Culot ... research and lab management services  BioData, producer ... is pleased to announce the appointment of Louis ... recently served as VP Marketing and Business Development at ... research and clinical applications. Previously, Culot worked ...
Breaking Biology Technology:Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3Louis Culot Appointed as BioData's CEO 2
... 4, 2011 Genesis Biopharma, Inc. (OTC Bulletin Board: ... cancer therapies, today announced that it closed private offerings ... entered into definitive agreements with accredited investors to purchase ... common stock for a purchase price of $1.00 per ...
... Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) ... Morgan Healthcare Conference on Monday, January 10, 2011.  The ... p.m. Eastern Time).  The session may be accessed through ... Investor Relations page.  An archived version of the presentation ...
... ST. LOUIS, Dec. 30, 2010 Sigma-Aldrich® Corporation ... has acquired all outstanding shares of Cerilliant Corporation ... analytical chemistry product portfolio and to continue to ... leading supplier of high quality reference standards and ...
Cached Biology Technology:Genesis Biopharma Raises $845,000 in Private Financings 2Sigma-Aldrich Acquires Cerilliant Corporation to Strengthen its Analytical Chemistry Portfolio 2Sigma-Aldrich Acquires Cerilliant Corporation to Strengthen its Analytical Chemistry Portfolio 3Sigma-Aldrich Acquires Cerilliant Corporation to Strengthen its Analytical Chemistry Portfolio 4
(Date:9/1/2014)... nocturnal animals, bats are perfectly adapted to a life without ... the reflected echoes to measure distance to obstacles or prey. ... echo delays. A study carried out by researchers at Technische ... this map dynamically adapts to external factors. , ... flies in too close to an object, the number of ...
(Date:8/31/2014)... a fast and accurate tool to diagnose tuberculosis ... newly developed test (TAM-TB assay) is the first ... children. The test features excellent specificity, a similar ... of a blood test. The promising findings are ... in children, particularly in tuberculosis-endemic regions. , The ...
(Date:8/31/2014)... not busy attacking us, germs go after each other. ... disaster for the infected microbes: Sometimes viruses actually carry ... expand its diet or better attack its own hosts. ... immune system would robotically destroy anything it recognized as ... have now revealed that one variety of the bacterial ...
Breaking Biology News(10 mins):Zooming in for a safe flight 2New tuberculosis blood test in children is reliable and highly specific 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3
... identifying a novel compound that primes a plant,s immune system, ... Chicago may be on a path to developing disease-resistant plants. ... team that includes Tim Tschaplinski of the Department of Energy,s ... the immunity response in Arabidopsis, a small flowering plant related ...
... tumors that arise from glial (supporting) cells of the ... grow fine extensions that infiltrate normal brain tissue and, ... surrounding tissue. Therefore, it is almost impossible to remove ... radical surgical removal of the tumor would substantially improve ...
... in German . Europe,s borders have ... from other parts of the world: from the American ... on, hybridise with, parasitise and out-compete native species. They ... landscapes and impact upon agriculture, forestry and fisheries. ...
Cached Biology News:Researchers discover primer to plant defense system 2Fluorescent cancer cells to guide brain surgeons 2Will Europe at last unite to combat thousands of alien invaders? 2Will Europe at last unite to combat thousands of alien invaders? 3
... These versatile vacuum cups provide flexible ... curved, or irregular surfaces. ,PFG: Flat ... Bellows cup ,PCG: Multiple Bellows cup ... from 25 to 200 mm , ...
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
UGT1A6 (D-20)...
... smallest electronic pressure controller available measuring 26 ... this unit specifically for the analytical instrumentation ... carrier gas flow control, microfluidic flow control, ... focusing, the OEM-EPC offers external pressure sensor ...
Biology Products: